Rhumbline Advisers Acquires 2,191 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Rhumbline Advisers grew its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 36.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,233 shares of the company’s stock after acquiring an additional 2,191 shares during the period. Rhumbline Advisers’ holdings in Contineum Therapeutics were worth $121,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in CTNM. BNP Paribas Financial Markets grew its position in Contineum Therapeutics by 1,248.6% in the third quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock worth $129,000 after acquiring an additional 6,243 shares in the last quarter. Barclays PLC grew its position in Contineum Therapeutics by 248.6% in the third quarter. Barclays PLC now owns 8,308 shares of the company’s stock worth $158,000 after acquiring an additional 5,925 shares in the last quarter. State Street Corp grew its position in Contineum Therapeutics by 23.7% in the third quarter. State Street Corp now owns 113,566 shares of the company’s stock worth $2,174,000 after acquiring an additional 21,760 shares in the last quarter. FMR LLC grew its position in Contineum Therapeutics by 115.4% in the third quarter. FMR LLC now owns 696,927 shares of the company’s stock worth $13,339,000 after acquiring an additional 373,327 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Contineum Therapeutics by 130.9% in the third quarter. Franklin Resources Inc. now owns 1,447,550 shares of the company’s stock worth $27,706,000 after acquiring an additional 820,542 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CTNM shares. Morgan Stanley restated an “overweight” rating and issued a $25.00 price objective on shares of Contineum Therapeutics in a research note on Friday. Robert W. Baird reduced their price objective on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.25.

Contineum Therapeutics Trading Up 9.3 %

Shares of Contineum Therapeutics stock opened at $7.40 on Tuesday. The stock has a market capitalization of $190.76 million and a price-to-earnings ratio of -1.51. Contineum Therapeutics, Inc. has a 1-year low of $5.92 and a 1-year high of $22.00. The firm has a fifty day simple moving average of $9.98 and a 200-day simple moving average of $14.31.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).